Sijin Wen, Ph.D.

Senior Statistical Analyst

Degrees

Ph.D. in Biostatistics, The University of Texas Health Science Center, Houston
M.S. in Statistics, The University of British Columbia, Vancouver, B.C., Canada
M.A. in Mathematics, York University, Toronto, Ontario, Canada

Areas of Interest

Data analysis
Simulations
Statistical computing
MCMC algorithms
Bayesian methods

Publications

Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-Kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. Journal of Interferon and Cytokine Research. 2011 Feb 16 [Epub ahead of print].

Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemotherapy and Pharmacology. 2011 Feb 3 [Epub ahead of print].

Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology 2011; 58(7):1037-1047.

Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. Journal of Clinical Oncology 2011; 29(18):2574-2581.

Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Research 2011; 31(4):1475-1482.

Tsimberidou AM, Letourneau K, Wen S, Wheler J, Hong D, Naing A, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clinical Cancer Research 2011; 17(12):4110-4118.

Tsimberidou AM, Letourneau K, Fu S, Hong D, Naing A, Wheler J, Uehara C, McRae SE, Wen S, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemotherapy and Pharmacology 2011; 68(1):247-253.

Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer 2011; 117(1):77-85.

Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Journal of Clinical Oncology 2010;28(24):3851-3857.

Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer 2010;116(17):4086-4094.

Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemotherapy and Pharmacology 2010; 66(6):1087-1093.

Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening. American Journal of Public Health 2010;100(Suppl1):S118-S124.

Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. Journal of Clinical Oncology 2010;28(3):453-459.

Gehmert S, Velapatiño B, Herrera P, Balqui J, Santivañez L, Cok J, Vargas G, Combe J, Passaro DJ, Wen S, Meyer F, Berg DE, Gilman RH. Interleukin-1 beta single-nucleotide polymorphism's C allele is associated with elevated risk of gastric cancer in Helicobacter pylori-infected Peruvians. American Journal of Tropical Medicine and Hygiene 2009; 81(5):804-810.

Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. Journal of Clinical Endocrinology and Metabolism 2009;94(11):4423-4432.

Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. Journal of Pediatric Hematology/Oncology 2009; 31(11):803-811.

Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Informatics 2009; 7:199-216.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. Journal of the National Cancer Institute 2009; 101(5):306-320.

Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the association between elevated body mass index and Barrett's esophagus: a systematic review and meta-analysis. The Annals of Thoracic Surgery 2009; 87(2):655-662.

Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, Hasselblatt M, Paulus W, Fuller G, Wolff JE, Gopalakrishnan V. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. Journal of Neuro-oncology 2009; 93(3):303-318.

Norman PH, Thall PF, Purugganan RV, Riedel BJ, Thakar DR, Rice DC, Huynh L, Qiao W, Wen S, Smythe WR. A possible association between aprotinin and improved survival after radical surgery for mesothelioma. Cancer 2009; 115(4):833-841.

Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clinical Cancer Research 2009; 15(1):81-90.

Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. Journal of Clinical Oncology 2009; 27(6):904-910.

Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. The Journal of Urology 2009; 181(1):81-87.

Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. European Urology 2009; 55(5):1135-1143.

Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. Journal of Clinical Oncology 2008; 26(36):5936-5942.

Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008; 113(8):2038-2045.

Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113(7):1605-1613.

Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 2008; 113(6):1370-1378.

Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clinical Cancer Research 2008; 14(12):3729-3736.

Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112(4):975-980.

Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111(11):5291-5297.

Tsimberidou AM, Kantarjian HM, Wen S, O’Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of SerumB2Microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clinical Cancer Research 2008; 14(3):721-730.

Tsimberidou AM, Wierda WG, Plunkett WK, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.. Journal of Clinical Oncology 2008; 26(2):196-203.

Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan R. Adaptive therapy for androgen independent prostate cancer: A randomized selection trial including four regimens. The Journal of the National Cancer Institute 2007; 99(21):1613-1622.

Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huang S, Huang M, Liu J, Sahin AA, Hunt KK, Bast Jr RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research 2007; 9:R57.

Badgwell B, Feig BW, Ross MI, Mansfield PF, Wen S, Chang GJ. Pneumoperitoneum in the cancer patient. The Annals of Surgical Oncology 2007; 14(11):3141-3147.

Tsimberidou AM, Wen S, O’Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do K-A, Freireich E, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2126 Patients: 20 Years of Experience at MD Anderson Cancer Center. Journal of Clinical Oncology 2007; 25(29):4648-4656.

Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson M, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical Cancer Research 2007; 13(19):5816-5824.

Do K-A, McLachlan GJ, Bean R, Wen S. Gene shaving versus mixture models for the clustering of microarray gene expression data. Cancer Informatics 2007; 2:25-43.

Sharma P, Shen Y, Wen S, Yamada S, Jungbluth A, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. Tumor-infiltrating lymphocytes are statistically significant prognostic indicators in muscle-invasive urothelial carcinoma. Proceedings of the National Academy of Sciences 2007; 104(10):3967-3972.

Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the MD Anderson Prognostic Scoring System. Leukemia and Lymphoma 2007; 48(6):1150-1160.

Efstathiou E, Troncoso P, Wen S, Do K-A, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clinical Cancer Research 2007; 13(4):1224-1231.

Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clinical Cancer Research 2006; 12:5442-5447.

Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clinical Lymphoma & Myeloma 2006; 7(1):51-58.

Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. Applied Bioinformatics 2006; 5(2):89-98.

Wang J, Do KA, Wen S, Tsavachidis S, McDonnell TJ, Logothetis CJ, Coombes KR. Merging microarray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Informatics 2006; 2:87-97.

Tsimberidou AM, O’Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. Journal of Clinical Oncology 2006; 24(15):2343-2351.

Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser RJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 2006; 107(3):631-639.

Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leukemia & Lymphoma 2006; 47(3):417-423.

Tsimberidou AM, Catovsky D, Schlette E, O’Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107(1):125-135.

Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. Journal of Clinical Oncology 2005; 23(31):7904-7910.

Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen SJ, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting nerve-sparing radical prostatectomy. The Journal of Urology 2005; 174(4 Pt 1):1262-1265.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical Cancer Research 2005; 11(2 Pt 1):678-689.

Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2005; 23(18):4070-4078.

Sanchez-Oritz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer 2004; 101(10):2195-2201.

Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis CJ, Troncoso P, Papandreou CN, McDonnell TJ. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clinical Cancer Research 2004; 10(20):6770-6778.

MacNab YC, Farell PJ, Gustafson P, Wen S. Estimation in Bayesian disease mapping. Biometrics 2004; 60(4):865-873.

Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O’Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin against human tumors. Clinical Cancer Research 2004; 10(1 PT 1):33-42.

Gustafson P, MacNab YC, Wen S. On the value of derivative evaluations and random walk suppression in Markov chain Monte Carlo algorithms. Statistics and Computing 2004; 14(1):23-38.

Do KA, Broom BM, Wen S. GeneClust. In: Parmigiani G, Garrett ES, Irizarry RA, Zeger SL, eds. The Analysis of Gene Expression Data: Methods and Software. New York, NY: Springer; 2003:342-361.

Siefker-Radtke A, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: The MD Anderson Cancer Center experience. The Journal of Urology 2003; 169(4):1295-1298.

Do K, McLachlan GJ, Bean R, Wen S. Some recent methods in clustering microarray gene expression data and applications. Technical Report, Department of Biostatistics, MD Anderson Cancer Center, 2002.

^{Updated June 29, 2011}